Rapport Therapeutics Soars 124% on Groundbreaking Epilepsy Trial Data—What’s Next for RAPP?

Summary
• Rapport Therapeutics (RAPP) surges 124% intraday, hitting a 52-week high of $42.27
• Phase 2a trial of RAP-219 shows 77.8% reduction in seizures and 24% seizure freedom
• CEO Abe Ceesay calls results 'best-in-class' with potential for Phase 3 trials in 2026

Rapport Therapeutics (NASDAQ: RAPP) is experiencing a historic trading day as shares skyrocket 124% to $32.21, fueled by groundbreaking Phase 2a trial results for its experimental epilepsy drug RAP-219. The stock has swung from a morning high of $42.27 to a low of $27.05, reflecting intense retail and institutional participation. With 13.19 million shares traded—75.5% of its float—the market is scrambling to assess the implications of RAP-219’s 77.8% seizure reduction and 24% seizure freedom in drug-resistant patients.

Phase 2a Trial Success Ignites Biotech Bull Run
Rapport’s 124% surge stems from its Phase 2a trial of RAP-219, which demonstrated statistically significant reductions in both electrographic long episodes (LEs) and clinical seizures. Patients achieved 77.8% reduction in clinical seizures (p=0.01) and 24% achieved seizure freedom (p<0.0001) over 8 weeks. The drug’s favorable safety profile—mild adverse events and low discontinuation rate—further bolstered investor confidence. CEO Abe Ceesay emphasized RAP-219’s potential as a first-in-class treatment for focal epilepsy, with plans to advance to Phase 3 trials in Q3 2026. The data’s robustness, combined with the unmet need in drug-resistant epilepsy, triggered a buying frenzy.

Options Playbook: Leveraging RAPP’s Volatility with Gamma-Driven Contracts
• MACD: 0.276 (Signal Line: 0.367, Histogram: -0.091) – bearish divergence
• RSI: 48.35 – neutral
• Bollinger Bands: $17.00 (Upper), $15.18 (Middle), $13.36 (Lower) – price far above range
• 200D MA: $13.80 – price at 233% premium
• Kline Pattern: Short-term bearish trend + bearish engulfing pattern

RAPP’s technicals suggest a volatile short-term outlook amid a long-term ranging pattern. Key levels to watch: $30 (psychological support), $42.27 (52-week high), and $27.05 (intraday low). The stock’s 124% move has created asymmetric options opportunities. Two top picks from the chain:

• RAPP20250919C30
- Type: Call
- Strike: $30
- Expiry: 2025-09-19
- IV: 117.16% (high volatility)
- Delta: 0.68 (moderate sensitivity)
- Theta: -0.164 (rapid time decay)
- Gamma: 0.052 (moderate sensitivity to price changes)
- Turnover: $128,612
- Leverage Ratio: 8.09%
- Why it stands out: High IV and gamma make this call ideal for a 5% upside scenario (targeting $33.82). If RAPP holds above $30, the contract’s delta and gamma could amplify gains as the stock rallies.

• RAPP20251017C30
- Type: Call
- Strike: $30
- Expiry: 2025-10-17
- IV: 91.10% (moderate volatility)
- Delta: 0.66 (moderate sensitivity)
- Theta: -0.061 (slower time decay)
- Gamma: 0.038 (lower sensitivity to price changes)
- Turnover: $28,867
- Leverage Ratio: 6.34%
- Why it stands out: This call offers a longer runway (October expiry) with manageable time decay. A 5% upside scenario (to $33.82) would yield a 100% price change ratio, aligning with RAPP’s potential to consolidate above $30.

Action Alert: Aggressive bulls may consider RAPP20250919C30 for a short-term pop above $30, while RAPP20251017C30 suits a more measured bet on sustained momentum. Both contracts benefit from RAPP’s 5% upside scenario, with the former offering higher gamma for rapid price swings.

Backtest Rapport Stock Performance
I attempted to locate any trading sessions since 2022 in which RAPP (ticker : RAPP.O) experienced an intraday price jump of 124 % or more, but the historical data returned no such occurrences. A surge of that magnitude is extremely rare for a listed U.S. security; in most cases, significant single–day gains tend to fall well below the 100 % mark.How would you like to proceed?1. Lower the trigger threshold (e.g., 20 %, 30 %, 50 %, etc.) and re-run the event study.2. Redefine the event (e.g., use close-to-close returns instead of intraday high-to-low change).3. Analyse a different type of event altogether (earnings surprises, volume spikes, technical signals, etc.).Let me know your preference and I’ll set up the revised backtest accordingly.

RAPP’s 124% Surge: A Catalyst or a Flash in the Pan?
Rapport’s 124% rally is a testament to the power of clinical data in biotech, but sustainability hinges on RAP-219’s Phase 3 readiness and regulatory clarity. The stock’s 52-week high of $42.27 and 75.5% turnover rate suggest a crowded trade, increasing the risk of profit-taking. Investors should monitor the $30 support level and the $42.27 resistance for directional clues. Meanwhile, sector leader Amgen (AMGN) is down 1.36%, signaling a potential divergence in biotech sentiment. For RAPP, the path forward depends on maintaining its 77.8% seizure reduction narrative and securing FDA alignment. Watch for a breakdown below $30 or a breakout above $42.27 to dictate next steps.